Brian Vadasz1, Mattan Arazi1, Yousef Shukha2, Ofir Koren1,3, Riad Taher4,5. 1. The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. 2. Internal Medicine Department E, Rambam HealthCare Campus, Ein IbrahimUmm alfahm, POD 4147, 300100, Haifa, Israel. 3. Heart Institute, Emek Medical Center, Afula, Israel. 4. Internal Medicine Department E, Rambam HealthCare Campus, Ein IbrahimUmm alfahm, POD 4147, 300100, Haifa, Israel. R_mahamid@rambam.health.gov.il. 5. Department of Endocrinology, Rambam HealthCare Campus, Haifa, Israel. R_mahamid@rambam.health.gov.il.
Abstract
BACKGROUND: Euglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter 2 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis. CASE PRESENTATION: We present a case of 64-year-old Caucasian male patient previously diagnosed with type 2 diabetes treated with a sodium-glucose cotransporter 2 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults. CONCLUSION: This case highlights the importance of prescribing sodium-glucose cotransporter 2 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.
BACKGROUND: Euglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter 2 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis. CASE PRESENTATION: We present a case of 64-year-old Caucasian male patient previously diagnosed with type 2 diabetes treated with a sodium-glucose cotransporter 2 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults. CONCLUSION: This case highlights the importance of prescribing sodium-glucose cotransporter 2 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.
Authors: G Gambelunghe; F Forini; S Laureti; G Murdolo; G Toraldo; F Santeusanio; P Brunetti; C B Sanjeevi; A Falorni Journal: Clin Endocrinol (Oxf) Date: 2000-05 Impact factor: 3.478
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Bruce A Perkins; David Z I Cherney; Helen Partridge; Nima Soleymanlou; Holly Tschirhart; Bernard Zinman; Nora M Fagan; Stefan Kaspers; Hans-Juergen Woerle; Uli C Broedl; Odd-Erik Johansen Journal: Diabetes Care Date: 2014-03-04 Impact factor: 19.112
Authors: Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch Journal: Diabetes Care Date: 2015-06-15 Impact factor: 19.112